Stock Analysis

Data Source: SEC EDGAR 13F

Updated Hourly

CALIDI BIOTHERAPEUTICS INC (CLDWW)

0 + Investors. Track Smart Money conviction in CLDWW. See who's accumulating, reducing, or initiating positions.

Net Flow Q/Q

↓ -13

Streak

1Q ▼

Buyers last Q

Smart Money Signals — CLDWW

Based on 2 hedge funds · latest filing: 2024 Q4 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their CLDWW positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🔻

Below peak — only 7% of 3.0Y high

7% of all-time peak

Only 2 funds hold CLDWW today versus a peak of 28 funds at 2022 Q1 — just 7% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 88% fewer funds vs a year ago

fund count last 6Q

15 fewer hedge funds hold CLDWW compared to a year ago (-88% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🔴

Heavy selling pressure — only 0% buying

0 buying13 selling

Last quarter: 13 funds sold vs only 0 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

➡️

Steady new buyers — ~0 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 4 → 1 → 1 → 0. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

⚠️

Saturation — most institutions already know this story

0 → 4 → 1 → 1 → 0 new funds/Q

New funds entering each quarter: 4 → 1 → 1 → 0. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.

2.5

out of 10

Low Exit Risk

Exit risk score 2.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Hedge Fund Ownership: CLDWW

How many hedge funds hold CLDWW — quarterly history vs. share price

Quarterly hedge fund ownership of CLDWW vs. share price

Stock Performance

Real-time

Smart Money Signal ?

Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

0 top-rated funds 0 high-conviction

Consensus

0.0

/ 10

breadth

Elite

0.0

/ 10

conviction

Hedge Fund Positioning: CLDWW

2026 Q1 Stats Unlock in 9 days 0 + Investors

Track Smart Money conviction in CLDWW. See who's accumulating, reducing, or initiating positions.

Metric	All 13F Filers (2025 Q4)	Prior (2025 Q3)	Change
Funds Holding	0	0	-
13F Shares	0	0	-
Total Value	$0	$0	-
New Positions	0	0	-
Increased Positions	0	0	-
Closed Positions	0	0	-
Reduced Positions	0	0	-
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Statistics: CLDWW

Valuation Measures Data as of: --

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Financial Highlights

Profitability

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Income Statement & Cash Flow

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Institutional Holders (2026 Q1)

0 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CLDWW. Verified SEC 13F-HR filings.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 2 institutional holders of CLDWW — 2025 Q4 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Exos Asset Management LLC	0.23%	105,000	$1.0M
2	COWEN AND COMPANY, LLC	0.00%	171,536	$2.2M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — CALIDI BIOTHERAPEUTICS INC (CLDWW)

What does the Smart Money Trend signal show for CLDWW?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CLDWW positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CLDWW?

Heavy selling pressure — only 0% buying: Last quarter: 13 funds sold vs only 0 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.